AbbVie Inc (ABBV) : Wheatland Advisors Inc reduced its stake in AbbVie Inc by 2.54% during the most recent quarter end. The investment management company now holds a total of 7,545 shares of AbbVie Inc which is valued at $502,271 after selling 197 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.AbbVie Inc makes up approximately 0.26% of Wheatland Advisors Inc’s portfolio.
Other Hedge Funds, Including , Agf Investments boosted its stake in ABBV in the latest quarter, The investment management firm added 118,169 additional shares and now holds a total of 1,369,562 shares of AbbVie Inc which is valued at $91,171,742. AbbVie Inc makes up approx 1.00% of Agf Investments’s portfolio.Huntington National Bank reduced its stake in ABBV by selling 124,817 shares or 24.24% in the most recent quarter. The Hedge Fund company now holds 390,010 shares of ABBV which is valued at $25,311,649. AbbVie Inc makes up approx 0.62% of Huntington National Bank’s portfolio.Security National Trust Co boosted its stake in ABBV in the latest quarter, The investment management firm added 6,900 additional shares and now holds a total of 30,876 shares of AbbVie Inc which is valued at $1,970,198. AbbVie Inc makes up approx 0.70% of Security National Trust Co’s portfolio.Alpha Windward reduced its stake in ABBV by selling 792 shares or 14.88% in the most recent quarter. The Hedge Fund company now holds 4,532 shares of ABBV which is valued at $290,773. AbbVie Inc makes up approx 0.21% of Alpha Windward’s portfolio.Thompson Rubinstein Investment Management Inc Or boosted its stake in ABBV in the latest quarter, The investment management firm added 9,543 additional shares and now holds a total of 81,783 shares of AbbVie Inc which is valued at $5,247,197. AbbVie Inc makes up approx 2.01% of Thompson Rubinstein Investment Management Inc Or’s portfolio.
AbbVie Inc closed down -0.47 points or -0.71% at $66.1 with 49,01,851 shares getting traded on Thursday. Post opening the session at $66.58, the shares hit an intraday low of $66.08 and an intraday high of $66.98 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.